China High Quality 1976/3/9 Factories – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We have now our possess revenue group, design staff, technical crew, QC team and package group. We now have strict excellent regulate procedures for each process. Also, all of our workers are experienced in printing subject for Nano Nickel Powder, Magnesium Stearate, Glutaraldehyde Technical Grade, We honor our core principal of Honesty in business, priority in company and will do our greatest to provide our customers with high-quality goods and fantastic provider.
China High Quality 1976/3/9 Factories – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM

STANDARD

Appearance

White to off-white solid

Purity

≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.


Product detail pictures:

China High Quality 1976/3/9 Factories –  99% Apixaban CAS 503612-47-3 – Baoran detail pictures


Related Product Guide:

We keep on with our business spirit of "Quality, Performance, Innovation and Integrity". We goal to create much more worth for our customers with our rich resources, state-of-the-art machinery, experienced workers and exceptional providers for China High Quality 1976/3/9 Factories – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Mumbai, Palestine, Belarus, To achieve reciprocal advantages, our company is widely boosting our tactics of globalization in terms of communication with overseas customers, fast delivery, the best quality and long-term cooperation. Our company upholds the spirit of "innovation, harmony, team work and sharing, trails, pragmatic progress". Give us a chance and we will prove our capability. With your kind help, we believe that we can create a bright future with you together.
  • The product classification is very detailed that can be very accurate to meet our demand, a professional wholesaler.
    5 Stars By Eileen from Juventus - 2017.08.16 13:39
    The company account manager has a wealth of industry knowledge and experience, he could provide appropriate program according our needs and speak English fluently.
    5 Stars By Hedy from Malaysia - 2018.12.25 12:43
    Write your message here and send it to us

    Related Products